WallStSmart
OKUR

OnKure Therapeutics, Inc.

NASDAQ: OKUR · HEALTHCARE · BIOTECHNOLOGY

$4.28
-4.04% today

Updated 2026-07-10

Market cap
$184.20M
P/E ratio
P/S ratio
EPS (TTM)
$-4.32
Dividend yield
52W range
$2 – $5
Volume
0.3M

OnKure Therapeutics, Inc. (OKUR) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$37000.00$50000.00$529000.00$560000.00$662000.00$830000.00
Gross profit$-37000.00$-50000.00$-529000.00$-560000.00$-662000.00$-830000.00
Gross margin
R&D$15.91M$28.12M$25.86M$32.12M$43.80M$48.26M
SG&A$3.90M$4.82M$10.59M$14.69M
Operating income$-19.55M$-39.82M$-29.77M$-36.93M$-54.39M$-62.95M
Operating margin
EBITDA$-19.43M$-39.72M$-29.13M$-34.75M$-51.71M$-58.69M
EBITDA margin
EBIT$-19.46M$-39.77M$-29.51M$-35.31M$-52.37M$-59.52M
Interest expense$0.00$300000.00$8000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-19.46M$-39.77M$-29.51M$-35.31M$-52.67M$-59.52M
Net income growth (YoY)-104.3%+25.8%-19.6%-49.2%-13.0%
Profit margin

Frequently asked questions

How much free cash flow does OKUR generate?

OKUR produced $-51.87M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is OKUR's balance sheet healthy?

OKUR holds $59.05M in cash and equivalents against — in long-term debt, on $56.18M of shareholder equity. That debt is best read against the cash flow the business throws off each year.